2 completed. 2 Early Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Early Phase 1 | 2 | Completed 2 |
Follow Refractory Diffuse Large B-Cell Lymphoma: new trials by email Literature Review of Refractory Diffuse Large B-Cell Lymphoma trials Research Report on Refractory Diffuse Large B-Cell Lymphoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Duvelisib Exposure to Enhance Immune Profiles of T Cells in Patients With Recurrent or Refractory Diffuse Large B-Cell Lymphoma, DEEP T CELLS Study Duvelisib, Tisagenlecleucel - Recurrent Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma | Early Phase 1 | Completed | Emory University | 4 | 2022-01-13 | 2025-01-20 |
| Tumor-Specific Clonotype, Metabolic Profile, and PET/CT in Predicting Chemotherapy Response in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma Chemotherapy, Computed Tomography, Fludeoxyglucose F-18 - Recurrent Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma | Early Phase 1 | Completed | M.D. Anderson Cancer Center | 35 | 2015-10-13 | 2022-10-28 |
Lymphoma, Large B-Cell, Diffuse (2)
Hemic and Lymphatic Diseases (2) · Immune System Diseases (2) · Immunoproliferative Disorders (2) · Lymphatic Diseases (2) · Lymphoma (2) · Lymphoma, B-Cell (2) · Lymphoma, Non-Hodgkin (2) · Lymphoproliferative Disorders (2) · Neoplasms (2) · Neoplasms by Histologic Type (2)
CTL019 chimeric antigen receptor (1) · Drug Therapy (1) · Fluorodeoxyglucose F18 (1) · Magnetic Resonance Spectroscopy (1) · duvelisib (1) · tisagenlecleucel (1)
Emory University (1) · M.D. Anderson Cancer Center (1)
United States (2)
Edmund K Waller, MD, PhD (1) · Jason Westin (1)
P30CA138292 (1)